ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Phathom Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 181.29% and Operating profit at -6.18% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.11
2
With a growth in Net Sales of 104.43%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -97.5 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 6.38 times
- NET SALES(Q) Highest at USD 58.3 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 12.25%, its profits have risen by 33.8%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Phathom Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Phathom Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Phathom Pharmaceuticals, Inc.
12.25%
-0.00
61.43%
S&P 500
19.75%
1.50
13.19%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
181.29%
EBIT Growth (5y)
-6.18%
EBIT to Interest (avg)
-11.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.38
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.90
EV to EBIT
-8.07
EV to EBITDA
-8.10
EV to Capital Employed
68.06
EV to Sales
7.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-843.59%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -97.5 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 6.38 times
NET SALES(Q)
Highest at USD 58.3 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -108.71 %
PRE-TAX PROFIT(Q)
At USD -30.37 MM has Grown at 67.8%
NET PROFIT(Q)
At USD -30.37 MM has Grown at 67.8%
-2What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 8.75% (YoY
Here's what is working for Phathom Pharmaceuticals, Inc.
Net Sales
Highest at USD 58.3 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 58.3 MM has Grown at 104.43%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 6.38 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Operating Cash Flow
Highest at USD -97.5 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -30.37 MM has Grown at 67.8%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -30.37 MM has Grown at 67.8%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -108.71 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Phathom Pharmaceuticals, Inc.
Raw Material Cost
Grown by 8.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
